Jeremy Green
10% owner at Zymeworks; Director at Absci; Director at Shattuck Labs. Based in New York, New York.
- Rank
- 2053rd of 14,644
- Companies held
- 1
- Largest holding
- ABSI, 100.0% of total
- Latest SEC filing
- Jul 22, 2026
- Listed but not counted
- $407M
What the $67.4M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Absci ABSI Common Stock | Indirectly (see filing footnote) | 8,262,136 | $8.16 | $67.4M | 100.0% | Form 4, Jun 12, 2024 |
Share counts are the amounts Jeremy Green reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on Jeremy Green's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Zymeworks ZYME Common Stock, par value $0.00001 per share | Through Redmile Group, LLC Held by a company or fund the insider manages | 6,075,918 | $26.86 | $163M | — | Form 4/A, Oct 13, 2022 |
| Zymeworks ZYME Common Stock, par value $0.00001 per share | Through Redmile Group, LLC Held by a company or fund the insider manages | 6,045,437 | $26.86 | $162M | — | Form 3, Oct 13, 2022 |
| Shattuck Labs STTK Common Stock | Indirectly (see filing footnote) Held by a company or fund the insider manages | 5,615,489 | $4.55 | $25.6M | — | Form 4, Mar 28, 2024 |
| Shattuck Labs STTK Common Stock, par value $0.0001 per share | Indirectly (see filing footnote) Held by a company or fund the insider manages | 5,539,724 | $4.55 | $25.2M | — | Form 4, Dec 4, 2024 |
| Fate Therapeutics FATE Common Stock | Indirectly (see filing footnote) Held by a company or fund the insider manages | 13,180,388 | $1.01 | $13.3M | — | Form 4, Dec 26, 2023 |
| Fate Therapeutics FATE Common Stock | Indirectly (see filing footnote) Held by a company or fund the insider manages | 12,884,277 | $1.01 | $13.0M | — | Form 4, Dec 20, 2024 |
| Atara Biotherapeutics ATRA Common Stock | Through Redmile Group, LLC Held by a company or fund the insider manages | 636,852 | $6.34 | $4.0M | — | Form 4, Jul 22, 2026 |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 2050 | Horacio D. Rozanski CEO, Booz Allen Hamilton Holding. Mclean, VA | $67.6M |
| 2051 | Matthew S. Bromberg President and CEO, Unity Software. San Francisco, CA | $67.5M |
| 2052 | Joth Ricci CEO, Dutch Bros. Grants Pass, OR | $67.5M |
| 2053 | Jeremy Green 10% owner, Zymeworks. New York, NY | $67.4M |
| 2054 | Murry Gerber Director, BlackRock. New York, NY | $67.4M |
| 2055 | Russell Craig Ellwanger Chief Executive Officer, Tower Semiconductor. Bedford, WY | $67.3M |
| 2056 | Richard M. Beyer Director, Micron Technology. Boise, ID | $67.3M |
Other Zymeworks insiders
All ZYME insiders- Gregory Austin Ciongoli$13.3MDirector. #6735 overall
- Kenneth Galbraith$6.1MChair & CEO. #12631 overall
Questions
How much stock does Jeremy Green own?
Jeremy Green holds $67,419,030 in listed stock based on SEC filings and current prices, mostly Absci (ABSI). That ranks 2053rd on the Stock Rich List.
Is this Jeremy Green's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.